Showing results (621-630 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|September 8, 2010
Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patientsNikolaos Tsavaris, Ioannis F Voutsas, Christos Kosmas, et al.
Investigational New Drugs|September 8, 2010
A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumorsEduardo Vilar, Viktor Grünwald, Patrick Schöffski, et al.
Investigational New Drugs|September 8, 2010
Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumabErin R Gardner, Martha Kelly, Eric Springman, et al.
Investigational New Drugs|November 1, 1990
3-Deazaguanine: report of a phase I trial and drug-related cardiac toxicityK Margolin, J Doroshow, L Leong, et al.
Investigational New Drugs|September 14, 2007
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cellsBrigette Ma, Boon Cher Goh, Eng Huat Tan, et al.
Investigational New Drugs|September 12, 2007
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)Joseph G Kattan, Fady S Farhat, Georges Y Chahine, et al.
Investigational New Drugs|August 1, 1991
Differences in N-acetylation of the experimental antitumor agent batracylin in the mouse and the ratM M Ames, D A Mathiesen, J M Reid
Investigational New Drugs|August 1, 1991
Effects of benzoylphenyl ureas on growth of B16 melanoma cells in vitro and in vivoH P Hofs, J G McVie
Investigational New Drugs|August 1, 1991
Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumorsG Gasparini, S Dal Fior, F Pozza, et al.
Investigational New Drugs|March 30, 2010
The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1-MMP expression and activityJérôme Devy, Farid Ouchani, Christelle Oudot, et al.
Pageof 372